期刊文献+

口服抗糖尿病药物开发应用新进展

暂未订购
导出
摘要 近年来,国内外糖尿病患者正在以惊人的速度逐年增加,该病已被列为继心脑血管、癌症之后的严重危害人类健康的第三大疾病[1].据世界卫生组织的报告:目前在世界范围至少有1.71亿人患有糖尿病.预计到2030年将上升到3.70亿人[2].糖尿病和与糖尿病有关疾病的费用已占世界卫生预算的4-5%.因此,国内外口服抗糖尿病药物具有巨大市场.现将口服抗糖尿病药物开发应用进展简介如下:
作者 刘征
出处 《黑龙江医药》 CAS 2005年第4期289-290,共2页 Heilongjiang Medicine journal
  • 相关文献

参考文献4

二级参考文献16

  • 1[3]Lone J,Stanley BP,Patrick MJ,et al.Novel vinyl N-(2-benzoyl)-L-tyrosine derivatives and their use as antidiabeticsetc[P].WO:03/011834 A1,2003-02-13.
  • 2[4]Lu XP,Li ZB,Li BY,et al.Substituted arylalcanoic acid derivatives as pan PPAR agonists with potent antihyperglycemic and antihyperlipidemic activity[P].USP:US60/429221,2002-12-26.
  • 3[5]Wang YX,Lee CH,Tiep S,et al.Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity[J].Cell,2003,113(1):159-170.
  • 4[6]Henke BR,Blanchard SG,Brackeen MF,et al.N-(2-benzoylphenyl)-L-tyrosine PPARγ agonists.1.Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents[J].J Med Chem,1998,41(25):5020-5036.
  • 5Raskin P.Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin[].Diabetes Care.2003
  • 6Delgado H.Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetes mellitus[].Diabetes and Metabolism.2002
  • 7Madsbad S.Comparison between repaglinide and glipizide in type 2 diabetes mellitus: a 1-year multicentre study[].Diabetic Medicine.2001
  • 8Mafauzy M.Repaglinide versus glibenclamide treatment of type 2 diabetes during random fasting[].Diabetes Research and Clinical Practice.2002
  • 9Hanefeld M,Fisher S.Differential type 2 diabetes therapy based on patho-physiological aspects[].Therapeutische Umschau.2002
  • 10Dornhorst A.Insulinotropic meglitinide analogues[].The Lancet.2002

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部